Business Wire

TX-MAVENIR

28.10.2021 15:02:08 CEST | Business Wire | Press release

Share
Mavenir Announces Its Cloud-native, Modular, and Microservices-based Converged Charging Solution (CCS)

Mavenir , the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announces its cloud-native, modular, and microservices-based Converged Charging Solution (CCS), which enables Communications Service Providers (CSPs) to creatively monetize Network-as-a-Service from 3G, 4G, and 5G networks. As a component of the Mavenir Digital Enablement (MDE) platform , this MACH-based (100% Microservices, API first, Cloud-native, and Headless) CCS makes it easy to create and quickly deploy new services in response to market demand.

Mavenir Digital Enablement can stand alone or overlay existing BSS and, with this CCS, enables CSPs to introduce disruptive use cases like new digital service brands or new digital MVNO services quickly and cost-effectively while avoiding extensive network-wide impacts. Mavenir’s CCS fully supports 3GPP Release 16 specifications and conforms to TM Forum Open API standards.

The extensible data model is vital for innovative CSPs looking to unlock and capitalize on new 5G revenue streams by quickly making changes to and incrementally evolving the system to handle new use-cases without losing time and capital on development. The highly flexible core data model is driven by an intuitive graphical rules engine that simplifies service creation with no-code/low-code design and templates that empower CSPs to create new plans and rules without additional coding.

“In the new, use-case-driven future, the importance of an agile and robust charging and monetization platform becomes paramount,” said Sandeep Singh, GM Digital Enablement Business Unit. “Mavenir's composable architecture makes the transition much easier, allowing CSPs to install this CCS alongside existing charging solutions, starting with a small collection of microservices, incrementally growing, and eventually migrating to the new solution.”

Added Singh, “The unique stateless architecture allows distribution of various CCS microservices to either a single centralized data center, or multiple distributed data centers, including edge data centers. This provides CSPs the advantage of supporting a robust and scalable solution with a small footprint. CSPs can then easily launch new Ultra-Reliable Low Latency Communication (URLLC) and massive Machine Type Communications (mMTC) use cases requiring edge deployment for ultra-low latency needs.”

Underpinned by a modular design, Mavenir provides CSPs with a variety of commercial solutions to fit their individual needs. Mavenir’s CCS can be deployed as a lightweight CHF solution for handling 5G Nchf traffic to generate network usage records without the need for any rating. Other packages include online, offline, or converged 5G rating and monetization handlers and 4G Diameter online traffic handlers for supporting both OCS and CCS use-cases in a unified solution.

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For information about Mavenir, visit: www.mavenir.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye